PDS Biotechnology Corporation received a new patent from the Japan Patent Office on December 9 2025, granting Patent No. 7783866 for its investigational immunotherapy Versamune HPV (PDS0101). The patent covers broad composition‑of‑matter claims and methods of use that protect the product’s unique antigen‑targeting platform and its combination with checkpoint inhibitors.
Continue reading for full analysis...
PDS Biotechnology Corporation confirmed that the U.S. Food and Drug Administration has accepted its request for a Type C meeting and has scheduled the meeting for December 2, 2025. The meeting will focus on the company’s accelerated approval strategy for PDS0101 (Versamune HPV), a subcutaneous immunotherapy targeting HPV16‑positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Continue reading for full analysis...